Full TitleA Phase I Study Of Split-Course Bridging Radiotherapy (SC-BRT) Prior To Commercial CD19 CAR T-Cell Therapies For Patients with Relapsed or Refractory B-Cell Lymphomas
CAR T cell therapy is a treatment for some people with recurrent or persistent lymphoma. With CAR T cell therapy, some of a patient’s own T cells (a type of white blood cell) are removed and genetically modified in a laboratory to recognize their own cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body. This approach is a form of immunotherapy.
Researchers are doing this study to see if radiation therapy given before standard CAR T cell therapy is safe for people with B cell lymphomas that have come back or continued to grow despite treatment. Radiation therapy before CAR T cell therapy may help decrease areas of bulky cancer and allow CAR T cells to be more effective in killing cancer cells. Radiation therapy may also induce changes in the composition of the areas surrounding cancer cells, which may make it easier for CAR T cells to kill them.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have B cell lymphoma and be planning to have CAR T cell therapy.
- At least 2 weeks must pass between the completion of previous treatment and receipt of the study therapy.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. M. Lia Palomba at 646-608-3711 or Dr. Brandon Imber at 631-212-6346.